In October 2014, hydrocodone-based painkillers were reclassified from Schedule III to Schedule II, a federal change that sharply tightened prescription rules and, in Tess Henry’s experience, helped redirect an existing dependence from pills toward heroin. Her account gives the policy change a human-scale consequence: the pills she had been buying became harder for her dealer to obtain, and he offered a cheaper, more available street drug instead. The episode sits at the intersection of prescribing practices, drug control, and gaps in treatment, without making the regulatory change alone responsible for the course of her addiction.

The prescribing climate

The rescheduling came after years in which opioid prescribing had expanded amid a broad effort to make pain assessment and treatment a higher medical priority. In 1996, when OxyContin was introduced, doctors and hospitals were adopting the idea of pain as the fifth vital sign. New pain-assessment standards followed, and the Joint Commission on Accreditation of Healthcare Organizations made pain assessment and treatment a mandatory standard in 1999. Hospitals faced incentives to satisfy patients and protect reimbursement, while the measurement of pain through patient ratings made an individual and subjective experience appear readily quantifiable.

Purdue Pharma promoted OxyContin as safe for a wide range of pain, with company representatives repeating the claim that addiction rates were below 1 percent. The company also planned branded materials to help hospitals meet the new standards. Later, physicians acknowledged that intensified attention to pain had helped increase opioid prescribing without a full understanding of the consequences. This history does not explain the hydrocodone rule by itself, but it establishes the medical environment in which prescription opioids had become widely used before regulators tightened controls.

The scale of prescribing was also part of the debate surrounding rescheduling. Between 1999 and 2010, narcotic prescriptions quadrupled, as did deaths. The change was therefore presented amid competing concerns: prescription drugs had become more accessible, but stricter controls could burden people who relied on them for legitimate pain treatment and could alter how people with dependence found drugs.

Tess’s path from prescriptions to pills

Tess’s dependence began in 2012 after an urgent-care visit for bronchitis resulted in two thirty-day prescriptions: codeine cough syrup and hydrocodone for throat pain. When the prescriptions ran out, she sought pills through a dealer. She later described recognizing withdrawal symptoms after looking up what she had been taking. At the beginning of her routine, she snorted about five pills a day, commonly Dilaudid, Roxicodone, Lortab, or Opana. Her experience followed a wider pattern reported in the book: four out of five people who became dependent on heroin had first encountered opioids through prescriptions.

The supply of pills then dried up, almost overnight, several months into the routine. Tess attributed the shortage to the Drug Enforcement Administration’s reclassification of hydrocodone-based drugs, which made them harder for her dealer to obtain. Her account distinguishes the regulatory change from the dealer’s response: the rule altered access to prescription medication, while the dealer adapted by offering another product. She took her first snort of heroin in powder form, using it as she had crushed pills.

The new restrictions and the contested response

Under the October 2014 rule, hydrocodone combination drugs such as Vicodin and Lortab moved to Schedule II, the same category as OxyContin. Prescriptions were limited to intervals of thirty days or less, and refills were prohibited. Patients needing more medication had to return to a doctor for a new prescription rather than having a refill called in to a pharmacy. Previously, a prescription could be automatically refilled as many as five times, covering up to six months.

The change drew opposition as well as support. In public feedback submitted to the Drug Enforcement Administration, patients warned that reduced availability might push people toward street drugs, particularly heroin. Chronic-pain patients also objected to the extra inconvenience and expense, arguing that people using medication responsibly should not bear the consequences of attempts to control illegal use. Public opinion reflected the divide: 52 percent supported the rescheduling and 41 percent opposed it. The policy therefore carried two stakes at once—limiting access to drugs with potential for misuse and avoiding harm to patients who depended on them.

Tess’s dealer adjusted quickly to the shift in supply. He offered heroin as cheaper and easier to obtain than pills, and Tess accepted it. Her story supports a specific account of how the transition occurred in her case; it does not establish that every patient affected by rescheduling followed the same route. The distinction matters: a change in prescribing rules, a dealer’s decision, and a person’s dependence were interacting forces, not interchangeable explanations.

Treatment after the transition

Tess’s later efforts to obtain care show that the path away from illicit opioids was also shaped by access and cost. In January 2013, she had already completed a ten-week residential treatment program in Jacksonville that included counseling and medical detox. She briefly received buprenorphine, but it was discontinued after three weeks, and she still owed $25,000 for the stay despite having insurance. The National Institute on Drug Abuse later emphasized that evidence supported long-term maintenance with medication alongside behavioral treatment and recovery support, rather than short detoxification programs aimed at abstinence.

During a later pregnancy, Tess entered the Life Center of Galax, one of the few Virginia facilities that accepted patients receiving medication-assisted treatment. She took Subutex, a buprenorphine medication then recommended for some pregnant patients. The expense of care remained substantial: private insurance covered most of the $20,000 treatment bill, while her father paid the $6,500 deductible from what remained of her college savings. Her experience illustrates that identifying an opioid problem and reaching sustained treatment were separate challenges; the restrictions on pills did not themselves provide a reliable route into care.

By early 2016, buprenorphine helped Tess feel normal and reduced her cravings, but access to treatment still required considerable out-of-pocket spending. Insurance covered 80 percent of the medication, while addiction-doctor visits were cash-only, with an initial charge of $700 and follow-up visits costing $90 to $100, potentially four times a month. At the time, federal rules limited certified medication-assisted-treatment doctors to 100 patients each. These later barriers should not be mistaken for direct consequences of hydrocodone rescheduling, but they clarify the larger stakes of the episode: restricting one source of opioids did not ensure timely access to effective care.

Significance

The reclassification appears in Tess’s story as a policy shift with an immediate, legible sequence: prescription pills became harder to obtain, her dealer changed the offer, and she moved to heroin. Its significance lies not in a claim that regulation caused her addiction, which had begun earlier, but in showing how an effort to control medication supply could meet an already established dependence without an equally accessible treatment alternative. The controversy surrounding the rule—between preventing misuse and protecting pain patients—was thus also a question about what happens when a prescription supply contracts faster than care becomes available.